Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.

In the study, most people with HIV and fatty liver disease on INSTI drugs were taking dolutegravir, which made up 41% of those on INSTIs.

For people with HIV and fatty liver on INSTI drugs, taking a placebo for a year leads to a 10.8% increase in belly fat.

Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.

Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.